Helping to preserve what makes people who they are.
Genentech is committed to creating a tomorrow where neurological disorders no longer limit human potential through groundbreaking research, advancing equitable access to care and by closely collaborating with the community.
There are hundreds of neurological disorders that impact nearly 100 million Americans. These disorders can alter the very essence of what makes us human—the way we think, communicate, move and remember.
At Genentech, we are continuing to advance groundbreaking research to discover and develop breakthrough medicines for the most common and rare neurological disorders that have eluded researchers.
As part of this research, we are prioritizing the recruitment of underrepresented communities. We are also deepening engagements with stakeholders across the healthcare system and enhancing support for people from all backgrounds to help ensure more equitable access to care.
We recognize that as populations around the world continue to age, the impact of neurological disorders is expected to increase. This will create new challenges we are prepared to meet by working closer with the community and key partners. This includes contributing to the Institute for Health Metrics and Evaluation (IHME) Brain Health Atlas and raising awareness about why brain health matters.
Through our work, we remain committed to pushing the boundaries of scientific understanding to solve some of the greatest challenges in neuroscience today.
Learn more about our commitment to neuroscience and read inspiring stories from people living with neurological disorders.
Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Our transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis.<\/p>\r\n\r\n\t\t\t\t\t
We celebrate our unique history as the pioneers of scientific breakthroughs that have an incredible track record of improving lives. And yet, our ambitions are bigger and bolder. Together, we are united in a bold quest to solve the world\u2019s most complex health challenges and serve society.<\/p> \r\n\r\n\t\t\t\t\t
Our ability to bring transformative medicines to patients depends on the positive experience, engagement and resilience of everyone who works here. Our employees are the heart of Genentech and the driving force behind the progress that brings important new medicines to the people who need them. We believe a great people experience is critical for revolutionizing healthcare and living Our Promise<\/a>. That\u2019s why we\u2019re committed to cultivating an environment where people feel valued, included and able to thrive.<\/p>\r\n <\/div>\r\n\r\n \r\n Genentech became a member of the Roche Group in March of 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech's South San Francisco campus serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech Research and Early Development continues to embrace the spirit of a \u201cstartup\u201d and operates as a separate business unit within Roche.\r\n <\/p>\r\n <\/div>","right_rail_html":null,"published":true,"is_unlisted":false,"hide_secondary_navigation":0,"node_parent":null}};A Member of the Roche Group<\/h3>\r\n\r\n